VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a 112% year-over-year revenue surge in the first half of 2026, reaching $1.4 million as it expanded its clinical and commercial operations.
The multi-national epigenetics firm demonstrated strong momentum across its core diagnostic verticals, including sepsis monitoring, human oncology detection, and companion animal health, positioning the company to address total market opportunities exceeding $26 billion.
Sepsis Validations And Point-Of-Care Progress
In sepsis, Critical Care Medicine published independent, peer-reviewed data confirming that the Nu.Q NETs H3.1 biomarker serves as an independent predictor of 28-day mortality and renal replacement therapy.
This validates the assay’s clinical utility for severe sepsis, which features a $2.8 billion total addressable market. Volition is preparing for the September 2026 recruitment start of France’s $7.3 million government-backed DETECSEPS evaluation.
